Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/4/15  and contains information from public web pages and contributions from the ZoomInfo community.

Anthony J. Gibney

Wrong Anthony J. Gibney?

Managing Director

Phone: (212) ***-****  
Email: t***@***.com
Local Address:  New York , New York , United States
Leerink Swann & Company
One Federal Street, 37th Floor
Boston , Massachusetts 02110
United States

Company Description: Leerink Partners is a leading investment bank, specializing in healthcare. Our knowledge, experience and focus enable us to help our clients define and achieve...   more

Employment History


  • B.A.
    Yale University
27 Total References
Web References
With indications that the long bubble ..., 4 Sept 2015 [cached]
With indications that the long bubble in biotech valuations may be primed for adjustment, Pharm Exec sits down with on of the investment community's leading biotech strategists, Tony Gibney, Managing Partner of Leerink Partners LLC, to better understand today's state of play in this critically innovative segment of the life sciences industry. In our Q&A, Gibney highlights key elements of a successful IPO and addresses the growing sensitivity of payers to the soaring biotech product cost curve. Gibney offers one novel solution-to raise the industry's profile with fresh R&D commitments around an "underfunded" primary care disease pipeline, where evidence shows such products can have a disproportionate impact in lowering healthcare costs overall.
GIBNEY: The industry is in a very healthy cycle overall; it's arguably the most productive environment that I have seen in my 23 years servicing the industry. Consolidation in the biopharma industry continues at an exceptional pace, and the transactions are driven by a wide variety Tony Gibney
GIBNEY: The low cost of capital and liquidity of the capital markets have played a role.
GIBNEY: Globalization became a priority for the pharma majors five to 10 years ago.
GIBNEY: The most direct impact that trapped overseas cash has had on the industry is to make ex-US domiciled companies incrementally more attractive as targets relative to their US-domiciled peers.
GIBNEY: The biotech arena is more competitive now than it has ever been with a large array of companies seeking to develop breakthrough drugs that can transform the patient experience.
GIBNEY: Many stakeholders express concern regarding the sustainability of drug pricing.
GIBNEY: The level of IPO activity today is the highest since 1999-2000.
GIBNEY: Quite the contrary.
GIBNEY: Some of the most successful recent IPOs have funded breakthrough discovery platforms with the potential to disrupt the status quo.
GIBNEY: These metrics are important-solid data is always helpful.
GIBNEY: Companies are often slow to recognize the vital importance of positioning their assets against the competition in a balanced manner that is constructive, even supportive, of the competition.
GIBNEY: Fund flows into or out of the sector have a substantial short-term impact on IPO performance.
GIBNEY: The JOBS Act enacted by Congress in 2012 has had an overall positive impact on biopharma IPOs.
GIBNEY: Market timing in this industry is notoriously tough to predict.
Anthony Gibney is Managing Director, Leerink Partners LLC. He can be reached at
Tony Gibney Managing ..., 11 June 2015 [cached]
Tony Gibney Managing Director, Leerink Partners LLC
David Rosenthal Dechert Partner, New York
Institutional investors | IR Café [cached]
In "A Street-Wise Conversation" in the September Pharmaceutical Executive, Tony Gibney of Leerink Partners, says:, 30 Jan 2015 [cached]
The panel was moderated by Tony Gibney, Managing Director of Leerink Swann LLC.
Morgan Lewis Partner Steve Cohen will ..., 15 Oct 2014 [cached]
Morgan Lewis Partner Steve Cohen will moderate a panel, including CEO Summit Chair Al Altomari, President, CEO and Director, Agile Therapeutics, Inc.; Kevin Davies, Managing Director, Co-Head of Healthcare Investment Banking, RBC Capital Markets; Michael Gaito, Managing Director, JP Morgan Healthcare Investment Banking; Tony Gibney, Managing Director, Leerink Partners LLC; and Michael Margolis, R.Ph., Managing Director, Healthcare Investment Banking, Roth Capital Partners, LLC.
Other People with the name "Gibney":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.